CGMs are transforming health tracking for non-diabetics, providing insights into glucose levels and influencing dietary choices and athletic performance.

Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

Jake Leach caught up with MedTech Dive during the ATTD conference to discuss new data on the company’s glucose monitors and an FDA warning letter.

PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning.

Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...

Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.

AI-enhanced glucose monitoring provides predictive analytics and personalized insights for better blood sugar management.

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous glucose monitors ...

Insulet (Nasdaq:PODD) announced today that it made its Omnipod 5 automated insulin delivery system available in several new ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...